2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4105 DNA damage Response–Associated clonal hematopoiesis is associated with neurotoxicity and worse survival after CAR T-cell therapy for lymphoma

June-Wha Rhee, MD, Scott R Goldsmith, MD2, Sitong Chen, MPH3, Keith Anderson4, Madison Barton5, Kavya Achanta, PhD6, Kate Farren7, Nathan Perez8, Mareen Kassabian, BS9, Lauren Doan10, Johann Charelus11, Derek Lance12, Alysia Bosworth, BA13, Lanie Lindenfeld14, Matthew Mei I, MD15, Geoffrey Shouse, DO PhD16, L. Elizabeth Elizabeth Budde, MD PhD17, Joo Song, MD18, Alex Francisco Herrera, MD19, F. Lennie Wong, PhD20, Stephen J. Forman, MD21, Saro H Armenian, MD, MPH22
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States
20 City of Hope National Medical Center, Duarte, California, United States
21 City of Hope National Medical Center, Duarte, California, United States
22 City of Hope National Medical Center, Duarte, California, United States

Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for relapsed or refractory lymphoma and is increasingly incorporated earlier in the treatment paradigm. However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a clinically consequential complication that can progress rapidly, require intensive supportive care, and contribute to non-relapse morbidity and mortality. Reliable pretreatment biomarkers of ICANS risk remain lacking. Clonal hematopoiesis (CH), characterized by the expansion of hematopoietic stem cell clones harboring somatic mutations, is enriched in cancer patients exposed to genotoxic therapies and may promote dysregulated myeloid inflammation, endothelial dysfunction, and neurovascular injury, processes implicated in ICANS pathogenesis. Although prior studies suggest that CH may influence CAR T-cell toxicity, its association with clinically significant ICANS, high-risk CH features, and cause-specific mortality remains poorly characterized.

Methods: We evaluated 403 consecutive patients who received CAR T-cell therapy for lymphoma between 2017 and 2025 at City of Hope and had available pretreatment peripheral blood DNA samples. Targeted deep sequencing of an 18-gene panel was performed at a median sequencing depth of approximately 1000× to identify CH variants with a variant allele frequency (VAF) ≥2%. The primary toxicity endpoint was clinically significant ICANS (grade ≥2), graded according to ASTCT criteria. Logistic regression models estimated odds ratios (ORs) for the association between CH and grade ≥2 ICANS, adjusting for demographic, disease-related, and treatment-related factors. One-year overall mortality was evaluated using Cox proportional hazards regression, while relapse-related mortality and non-relapse mortality were assessed using Fine-Gray competing-risks regression models according to CH status. 

Results: The median age at CAR T-cell infusion was 64.7 years (range, 21.5-85.6 years); 62.5% were male. The cohort was 44.9% non-Hispanic White, 35.5% Hispanic, 15.9% Asian, and 4.7% Black or another race/ethnicity. CAR T-cell products included axicabtagene ciloleucel (61.5%), lisocabtagene maraleucel (19.9%), tisagenlecleucel (6.2%), and brexucabtagene autoleucel (4.5%). Overall, 111 patients (27.5%) harbored at least one CH variant, and 39 (35%) had ≥2 variants. CH prevalence increased with age, from 3.7% among patients aged <45 years, to 13.2% at 45–<55 years, 18.3% at 55–<65 years, 39.6% at 65–<75 years, and 45.2% at ≥75 years (chi-square p<0.001). The most frequently mutated genes were DNMT3A, PPM1D, TET2, and TP53. Overall, 123 patients (30.5%) developed grade ≥2 ICANS following CAR T-cell therapy. ICANS frequency differed across CH subtypes: patients with DNA damage response (DDR)-associated CH, including PPM1D and TP53 mutations, had higher rates than patients non-DDR CH or no CH (51.4% vs. 29.7% vs. 28.1%, respectively; p=0.015). Compared with patients without CH, DDR-CH was associated with 2.7-fold higher odds of ICANS (OR, 2.70, 95% CI, 1.35–5.41), whereas non-DDR CH was not (OR 1.08, 95% CI 0.62–1.90). Greater CH burden and clone size were also associated with higher odds of ICANS: patients with multiple CH variants had an OR of 3.00 (95% CI, 1.53–5.86), and those with VAF >10% had an OR of 2.44 (95% CI, 1.26–4.74) compared with patients without CH. In multivariable analysis, DDR-CH remained independently associated with a nearly threefold higher odds of ICANS (OR 2.95, 95% CI 1.44–6.05; p=0.003). Finally, patients with DDR-CH also had significantly worse 1-year overall survival than those with non-DDR CH or no CH (58.8% vs. 74.3% vs. 76.7%, respectively; p=0.03), driven primarily by a higher risk of non-relapse mortality (subdistribution HR 3.15, 95% CI 1.13–8.77).

Conclusions: In this large, well-characterized cohort of lymphoma patients receiving CAR T-cell therapy, CH was highly prevalent, with DNMT3A, PPM1D, TET2, and TP53 as the most frequently mutated genes. DDR-CH was independently associated with clinically significant ICANS and worse 1-year survival, largely reflecting higher non-relapse mortality. These findings identify DDR-CH as a potential pretreatment biomarker for risk stratification before CAR T-cell therapy and support further investigation of CH-informed surveillance and toxicity-mitigation strategies.

June-Wha Rhee, MD: No relevant conflicts of interest to declare.